Seaport Therapeutics that has been founded by PureTech Health has announced that it has raised USD 225 Million from General Atlantic and other investors like Third Rock Ventures, Sofinnova Investments, and ARCH Venture Partners.
This company is now backed by some of the biggest and largest Venture capitalists in the drug development and the company is now aiming to disrupt the psychiatric drugs market.
Overall, to date, Seaport Therapeutics has raised around $325M in venture capital funding, and after this Series B financing round, PureTech Health will retain 36% shares of Seaport Therapeutics. In the past, PureTech Health has made many remarkable disruptions in the biotechnology sector.
With this mega funding, Seaport Therapeutics, which is working on generalized anxiety disorder and major depressive disorder treatment using therapeutics, will try to make major advancements.
Daphne Zohar is the CEO, Founder, and Board Member of Seaport Therapeutics, and previously she served as the CEO of PureTech Health and has been recognized as one of the top innovators and leaders in the Biotechnology field.
